Faraday Future Intelligent Electric Inc. (NASDAQ: FFAI) and Qualigen Therapeutics, Inc. (NASDAQ: QLGN) have announced a significant partnership through a private investment in public equity (PIPE) following the execution of a securities purchase agreement. This new collaboration not only entails an equity investment in QLGN’s common and preferred stock but also marks Faraday Future’s foray into the crypto and Web3 space.
The PIPE financing is spearheaded by Faraday Future, under the direction of its Founder and Global Co-CEO, YT Jia. The deal has garnered additional backing from a variety of prominent investors, including SIGN Foundation—a blockchain firm supported by Binance Labs—alongside notable firms like Sequoia Capital, IDG, and Circle. This financing initiative has reached an estimated total of $41 million, with Jerry Wang, Faraday Future’s President, also taking part.
According to the terms outlined in the agreement, Faraday Future will invest around $30 million in Qualigen at a price effective of $2.246 per share. This transaction will result in Faraday Future owning about 55% of QLGN’s outstanding common shares. Additionally, YT Jia plans to make a personal investment of roughly $4 million, which will represent around 7% ownership of QLGN and will be subject to a two-year lock-up period.
As part of the leadership changes following the deal’s closing, YT Jia will take on the role of Chief Advisor at QLGN, while Jerry Wang will be appointed Co-CEO. Faraday Future’s CFO, Koti Meka, will also assume the CFO position at Qualigen. Furthermore, Faraday Future is afforded the right to nominate two of the five independent directors on Qualigen’s board. If stockholder approval is granted, this nomination right could be expanded to four out of seven seats. The company will also retain participation rights for any future financing undertaken by Qualigen.
Completion of the PIPE and stockholder approval is poised to result in Faraday Future and YT Jia holding over 62% of QLGN’s common stock. This strategic investment is seen as a way for Faraday Future to enhance its electric vehicle (EV) initiatives while allowing QLGN to center its efforts on growth within the crypto and Web3 sectors. The partnership aims to foster synergies, create new financing opportunities, and maximize shareholder value without diluting Faraday Future’s shares.
YT Jia remarked on the significance of this investment, stating that it represents a crucial milestone in the evolution of Faraday Future. He emphasized the dual synergy between EV technologies and cryptocurrency as essential to the company’s future vision.
Kevin Richardson, CEO of Qualigen, expressed enthusiasm about this transformative transaction, highlighting the company’s commitment to embracing emerging technologies that could reshape its future.
The financial transaction was facilitated by Univest Securities, LLC, which acted as the sole placement agent. Faraday Future received legal representation from Pryor Cashman, while Qualigen was represented by Lucosky Brookman and retained a capital market advisor for future activities.
In addition, Faraday Future’s overarching mission focuses on disrupting the automotive landscape through innovative technologies and user-centric experiences, exemplified by its flagship model, the FF91. The company aims to further enhance its market presence with upcoming mass production models targeting a broader audience.
Qualigen Therapeutics is dedicated to developing therapies for cancers with potential Orphan Drug Designation, thus furthering its commitment to scientific advancement in the medical field. The alignment between these two companies marks an intriguing intersection of technology and healthcare, suggesting a future rich in collaborative growth opportunities.
